GLP-1 / Weight Loss

Ozempic vs Saxenda: Comparing GLP-1 Weight Loss Options

Verdict Summary

Ozempic (semaglutide) produces significantly greater weight loss than Saxenda (liraglutide) and requires only once-weekly dosing vs daily. Saxenda has a longer track record in obesity specifically.

Medical Disclaimer: This comparison is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer →

At a Glance

DimensionOzempicSaxenda
Active CompoundSemaglutideLiraglutide
Dosing FrequencyOnce weeklyOnce daily
Avg. Weight Loss~15% body weight~8% body weight
AdministrationSubcutaneous injectionSubcutaneous injection
Cost~$900/month~$1,300/month

Ozempic Deep Dive

Semaglutide has a longer half-life than liraglutide, enabling once-weekly dosing. The STEP trials demonstrated ~15% average weight loss at the 2.4mg Wegovy dose, significantly outperforming liraglutide in head-to-head studies.

Saxenda Deep Dive

Liraglutide (Saxenda) was the first GLP-1 agonist approved specifically for obesity (2014). It requires daily injection but has a well-established safety profile and is often preferred when weekly injections are not tolerated.

How to Choose

Choose Ozempic if…

  • You want maximum weight loss efficacy
  • Weekly dosing convenience is important
  • Cost per unit of weight loss matters

Choose Saxenda if…

  • Daily dosing flexibility is preferred
  • You want the longest-established obesity-specific GLP-1
  • You have had adverse reactions to semaglutide

Still Unsure?

Get a personalized recommendation

Take the 5-minute PeptidePilot quiz. Our algorithm evaluates your goals, body, and lifestyle to recommend the right peptide for you — vendor-neutral.

Frequently Asked Questions

More Comparisons